Emollient bath and shower products, paraffin-containing
Brand names: Oilatum, Balneum, Hydromol Bath
These are paraffin-containing emollient bath additives and shower preparations used to soften and moisturise the skin in dry skin conditions such as eczema and ichthyosis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
The paraffin oils coat the skin during bathing to form an occlusive layer that reduces transepidermal water loss and restores the skin barrier.
Prescribing in practice
- Paraffin-based products soak into fabrics and create a serious fire hazard, so patients and carers must be warned that clothing, bedding and dressings can ignite more easily near naked flames or cigarettes.
- Treated baths and showers become very slippery, posing a falls risk that warrants non-slip precautions.
- Direct evidence that bath additives add benefit over leave-on emollients is limited, so they should be used as an adjunct rather than a substitute for regular emollient application.
Monitoring
No laboratory monitoring is needed; review skin condition, tolerability and adherence to fire-safety advice at follow-up.
Counselling the patient
- Keep away from naked flames and do not smoke; fabrics in contact with these products burn very easily even after washing.
- Take care getting in and out of the bath or shower as the surface becomes slippery.
- Pat the skin dry and apply your leave-on emollient afterwards.
Evidence & guidelines
The MHRA has issued repeated safety alerts on the fire risk of paraffin-based and other emollients, and the BATHE trial questioned added benefit of bath emollients in childhood eczema.
Reference: NICE CKS Eczema; BAD; MHRA Drug Safety Update; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- HE-MACS (History and ECG-Based Manchester ACS Risk Score) · ACS Risk Stratification
- Weight-Based Levothyroxine Dose Calculator · Thyroid
- Number Needed to Treat (NNT) / Number Needed to Harm (NNH) · Evidence-Based Medicine
- HIV Opportunistic Infection Risk (CD4-Based) · HIV / Immunodeficiency
- BASDAI — Bath Ankylosing Spondylitis Disease Activity Index · Spondyloarthritis
- BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) · Axial Spondyloarthropathy
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD